Does retatrutide work for type 2 diabetes?
Retatrutide works for type 2 diabetes through GLP-1, GIP, and glucagon pathways. Phase 2 data showed blood sugar improvement; TRIUMPH-2 will fill in the A1c detail.
Updated May 29, 2026 · 5 min read
Yes — retatrutide targets type 2 diabetes through three overlapping mechanisms that all reduce blood sugar. The GLP-1 component stimulates insulin release and slows gastric emptying. The GIP component amplifies insulin secretion and may improve beta cell function. The glucagon component raises some complexity but the net glycemic effect, in a drug that also drives significant weight loss, is favorable. Phase 2 data confirmed blood sugar improvements in participants, and the Phase 3 TRIUMPH-2 trial is generating the dedicated dataset for T2D labeling.
Why three mechanisms matter for blood sugar
Retatrutide is a triple agonist — it activates three distinct receptors simultaneously:
GLP-1 (glucagon-like peptide-1) receptor: This is the core glycemic mechanism shared with semaglutide and tirzepatide. GLP-1 agonism:
- Stimulates the pancreas to release insulin in a glucose-dependent manner (meaning it only works when blood sugar is elevated — this is why GLP-1 drugs don't cause hypoglycemia the way older diabetes drugs do)
- Suppresses inappropriately elevated glucagon release from the pancreas
- Slows gastric emptying, flattening post-meal blood sugar spikes
GIP (glucose-dependent insulinotropic polypeptide) receptor: GIP is the second incretin hormone. It also stimulates insulin release in a glucose-dependent manner and may have direct effects on beta cell survival and proliferation — potentially helping to preserve insulin-secreting capacity over time. This is tirzepatide's second mechanism and the one that gives it an A1c advantage over pure GLP-1 agonists.
Glucagon receptor: Glucagon raises blood sugar by stimulating the liver to produce glucose. This seems counterproductive in a diabetes drug. In the context of retatrutide's overall mechanism, the glucagon agonism is believed to primarily affect hepatic fat and energy metabolism rather than producing net hyperglycemia — especially when counterbalanced by potent GLP-1 and GIP agonism. The net metabolic effect on blood sugar is favorable, but this element adds nuance that's being studied carefully in the Phase 3 program.
What the Phase 2 data showed on blood sugar
The Phase 2 retatrutide trial published in the New England Journal of Medicine (July 2023) enrolled adults with obesity — the population was not primarily T2D patients. However, secondary metabolic endpoints including fasting glucose and insulin sensitivity markers were collected.
The results showed:
- Fasting plasma glucose decreased across retatrutide dose groups
- Insulin sensitivity markers improved, consistent with the weight loss and direct receptor effects
- The improvements scaled with the degree of weight loss — higher-dose groups, which lost more weight, showed larger glycemic improvements
The important caveat: because the Phase 2 trial enrolled adults with obesity (and not specifically T2D), A1c data was not reported as a primary outcome. People with T2D were excluded or underrepresented in the published Phase 2 cohort. The Phase 2 data tells us the glycemic direction is favorable; it doesn't give us the dedicated A1c reduction numbers that clinicians need to place retatrutide in the diabetes treatment landscape.
TRIUMPH-2: the dedicated T2D trial
Eli Lilly's Phase 3 TRIUMPH program includes a specific trial arm for type 2 diabetes. TRIUMPH-2 is enrolling adults with obesity and type 2 diabetes and is powered to demonstrate A1c reduction as a primary endpoint.
The TRIUMPH trials launched in 2024 and follow a similar design logic to the SURPASS program for tirzepatide. SURPASS-2, SURPASS-3, and others established tirzepatide's A1c reductions (1.5–2.3 percentage points across trials) that enabled its FDA approval for T2D as Mounjaro.
TRIUMPH-2 results are not yet publicly available as of this writing. When they report, the key numbers to watch will be:
- Mean A1c reduction from baseline (likely 1.5–2.5 percentage points, extrapolating from mechanism and weight loss magnitude)
- Proportion achieving A1c < 7.0% (standard T2D control target)
- Hypoglycemia rates (expected to be low given the glucose-dependent mechanism)
- Comparison arms (likely versus a GLP-1 agonist and/or insulin)
How retatrutide compares to existing T2D options
Semaglutide (Ozempic) at 2 mg weekly achieves mean A1c reductions of approximately 1.5–2.0 percentage points. Tirzepatide (Mounjaro) at 10–15 mg weekly achieves 2.0–2.3 percentage points — some of the largest A1c reductions seen from any non-insulin T2D therapy.
If retatrutide delivers weight loss that exceeds tirzepatide (as Phase 2 data suggested), and if weight loss drives a meaningful share of the glycemic benefit, retatrutide could potentially achieve A1c reductions in the 2.0–2.5+ range. But this is extrapolation, not published data — the TRIUMPH-2 numbers are needed before making that call.
For T2D patients currently on semaglutide or tirzepatide who are not at A1c target, retatrutide's potential triple-mechanism benefit is a reason to watch the TRIUMPH readouts closely. For patients who are well-controlled on existing therapy, the case for switching is less clear until head-to-head data exists.
What this means for T2D patients today
Retatrutide is not yet FDA-approved for any indication, including T2D. No one should be waiting on retatrutide instead of treating diabetes today — the metabolic consequences of uncontrolled T2D accumulate continuously.
If you have T2D and aren't at glycemic goal on your current regimen, semaglutide or tirzepatide are both available and highly effective. When retatrutide becomes available, a switch or escalation can be considered based on the data and your clinician's judgment.
The most useful thing to know now is that retatrutide's mechanism is well-positioned to work for T2D — the biology is consistent with meaningful glycemic benefit, and the Phase 3 program is designed to prove it.